Expert review of anticancer therapy
-
Expert Rev Anticancer Ther · Sep 2020
ReviewCombination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors.
Despite significant advances in the treatment of metastatic urothelial carcinoma, including the advent of immune checkpoint inhibitors, this disease is still challenging to treat and associated poor outcomes remain. Genomic characterization of advanced-stage urothelial carcinoma is widening the field of potential treatments due to the identification of novel biologic drivers. ⋯ Several challenges need to be faced in the development of new potential therapeutic strategies, such as inter/intratumoral heterogeneity and the lack of validated biomarkers.